Immunoassay

Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Thursday, May 2, 2024
FDA, Efficacy, Inflammation, DSM-IV codes, C5, Research, Abstract, Geographic atrophy, Paratriathlon, Primate, Sodium iodate, Immunoassay, AAV, Retina, ONL, Patient, Neurology, PALO, Kriyā, Mouse, Annual general meeting, Therapy, ARVO, Vaccine

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Key Points: 
  • PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.
  • Kriya’s pipeline includes gene therapies across several therapeutic areas including ophthalmology, metabolic disease and neurology.
  • Broad coverage was achieved from the injection site to the posterior pole, including the macula and retina.
  • The study demonstrates, in a dose dependent manner, the potential of AAV.CR2-CR1 to preserve the photoreceptor-containing outer nuclear layer (ONL).

Global Infectious Disease In vitro Diagnostics Market Report 2024: Immunoassay, Molecular Diagnostics, Microbiology Analysis and Forecasts 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2024
Infectious Diseases, Health Technology, Health, Medical Supplies, USD, Public, Porter's five forces analysis, Laboratory, SWOT, Population growth, Infection, Bacteria, Immunoassay, Urbanization, Molecular diagnostics, Human, Diagnosis, Parasitism, Patient, Microbiology, Virus, Fungus, Point, Prevalence, Product type, Medical device

The "Global Infectious Disease In vitro Diagnostics Market (2024 Edition): Analysis By Technology (Immunoassay, Molecular Diagnostics, Microbiology, Other Technologies), By Product Type, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Disease In vitro Diagnostics Market (2024 Edition): Analysis By Technology (Immunoassay, Molecular Diagnostics, Microbiology, Other Technologies), By Product Type, By End User, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Disease In vitro Diagnostics market showcased growth at a CAGR of 2.45% during 2020-2023.
  • The report analyses the Infectious Disease In vitro Diagnostics Market By Technology (Immunoassay, Molecular Diagnostics, Microbiology, Other Technologies)
    The report analyses the Infectious Disease In vitro Diagnostics Market By Product Type (Instruments, Reagents, and Services).
  • The report analyses the Infectious Disease In vitro Diagnostics Market By End Users (Point of care, Central Laboratories, and Other End Uses).

OTC/DTC Infectious Disease Diagnostics Market Strategies and Trends Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
Infectious Diseases, Biotechnology, Health, PCR, Channel, Infection, Country, COVID-19, Application, Lead, DTC, OTC, Immunoassay, CRISPR, Market analysis, Pharmaceutical industry

The "OTC/DTC Infectious Disease Diagnostics Strategies and Trends, COVID-19 Adjusted Forecasts: by Application, by Channel, by Country.

Key Points: 
  • The "OTC/DTC Infectious Disease Diagnostics Strategies and Trends, COVID-19 Adjusted Forecasts: by Application, by Channel, by Country.
  • With Market Analysis, Executive Guides, Customization and COVID-19 Market Opportunity Analysis."
  • Over the Counter and Direct to Consumer diagnostics are set to help solve the pandemic problem.
  • Exciting technical developments especially in the seesaw between PCR and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test in Identifying Amyloid and Tau in the Brain

Retrieved on: 
Monday, January 22, 2024
Cerebrospinal fluid, Classification, Pathology, Research, Diagnosis, CSF, Neuro, PET, Immunoassay, University, Amyloid, JAMA, Plasma, AUC, Biomarker, Neurology, Single, Brain, Test management, Blood, Medical imaging

CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leader in Alzheimer's diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain. The article, "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer's Disease Pathology," was authored by Dr. Nicholas Ashton and colleagues from the University of Gothenburg, Sweden.

Key Points: 
  • With the novel ALZpath pTau217 assay and test, ALZpath is transforming Alzheimer's disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide.
  • The ALZpath pTau217 assay showed high diagnostic accuracy in identifying elevated amyloid (AUC, 0.92-0.96; 95%CI 0.89-0.99) and tau (AUC, 0.93-0.97; 95%CI 0.84-0.99) in the brain across all cohorts.
  • Longitudinally, ALZpath's pTau217 test in blood showed an annual increase in individuals with amyloid plaques, with the highest increase observed in those who also had tau pathology.
  • The ALZpath pTau217 test will also be commercially available on other research and diagnostic platforms in support of global accessibility and scalability.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, General Health, Biometrics, Health, Pharmaceutical, Antibody, Risk, Growth, Fujirebio, Sysmex Corporation, Antigen, Agreement, Immunoassay, CDMO

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).
  • The Agreement is based on a basic agreement on business collaboration in the field of immunoassay*1 which the two companies signed in October 2023.
  • In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.
  • Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

Global Hemoglobin A1C (HbA1C) Testing Strategic Research Report 2023: Market to Reach $2.3 Billion by 2030 from $1.4 Billion in 2022 - Benefits of POC HbA1c Tests Over Lab Tests Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, December 8, 2023
Medical Devices, Health, Glycated hemoglobin, POC, HPLC, American Diabetes Association, HB, Growth, COVID-19, Medical laboratory, Immunoassay, High-performance liquid chromatography, Diabetes, Pharmaceutical industry

The "Hemoglobin A1C (HbA1C) Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemoglobin A1C (HbA1C) Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The report discusses the impact of the COVID-19 pandemic on the utilization of Hemoglobin A1C (HbA1C) laboratory tests, highlighting a new challenge of underutilization.
  • It also provides insights into the competition within the HbA1C testing market, including the global key competitors' percentage market share in 2022.
  • The global market analysis and prospects for HbA1C testing are presented, with a focus on rapid growth in the world HbA1C testing market.

Aegis Sciences Corporation Announces Expanded Testing for Marijuana

Retrieved on: 
Tuesday, December 5, 2023
Science, Research, Natural Resources, Pharmaceutical, General Health, Health, Cannabis, Other Health, Urine, Mass spectrometry, Cannabinoid, Reflex, Senior, Immunoassay, THC, Airflow Sciences Corporation, Dietary supplement, Aegis, Cannabidiol

Aegis Sciences Corporation , a health care testing lab based in Nashville, Tenn., is pleased to announce it will be updating their urine testing for marijuana and other cannabinoids to include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC.

Key Points: 
  • Aegis Sciences Corporation , a health care testing lab based in Nashville, Tenn., is pleased to announce it will be updating their urine testing for marijuana and other cannabinoids to include Delta‐8 Carboxy‐THC and Cannabidiol, in addition to Delta‐9 Carboxy‐THC.
  • The interpretation of marijuana results differs when considering presumptive vs definitive testing.
  • Aegis’s assay will continue to undergo presumptive testing by immunoassay with reflex to definitive testing by mass spectrometry.
  • “Expanding our marijuana assay to include other cannabinoids demonstrates our commitment to providing the most relevant testing available to healthcare providers,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Retrieved on: 
Thursday, November 30, 2023
Health, Biometrics, Other Health, General Health, Pharmaceutical, Biotechnology, Fujirebio, Sysmex Corporation, CSF, Disease, Basic, Alzheimer's disease, Immunoassay, Partnership, CDMO, Pharmaceutical industry

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.
  • Under the terms of the new agreement, in the field of neurodegenerative diseases including Alzheimer's Disease, Fujirebio will develop reagents for Sysmex's HISCL™-Series for cerebral spinal fluid (CSF)-based testing as well as blood-based testing.
  • This will accelerate the expansion of Sysmex’s testing parameters in the diseases field, further propelling the expansion of its global footprint in immunoassay.
  • Fujirebio and Sysmex will further collaborate to develop and launch the tests as early as possible.